Prognostic implications of changes in amino-terminal pro–B-type natriuretic peptide in acute decompensated heart failure: insights from ASCEND-HF

Grodin, J. L. et al. (2019) Prognostic implications of changes in amino-terminal pro–B-type natriuretic peptide in acute decompensated heart failure: insights from ASCEND-HF. Journal of Cardiac Failure, 25(9), pp. 703-711. (doi: 10.1016/j.cardfail.2019.04.002) (PMID:30953792)

Full text not currently available from Enlighten.

Abstract

Background: Amino-terminal pro–B-type natriuretic peptide (NTproBNP) is closely associated with prognosis in acute decompensated heart failure (ADHF). As a result, there has been great interest measuring it during the course of treatment. The prognostic implications in both short-term and follow-up changes in NTproBNP need further clarification. Methods: Baseline, 48–72 hour, and 30-day NTproBNP levels were measured in 795 subjects in the ASCEND-HF trial. Multivariable logistic and Cox-proportional hazards models were used to test the association between static, relative, and absolute changes in NTproBNP with outcomes during and after ADHF. Results: The median NTproBNP at baseline was 5773 (2981–11,579) pg/mL; at 48–72 hours was 3036 (1191–6479) pg/mL; and at 30 days was 2914 (1364–6667) pg/mL. Absolute changes in NTproBNP by 48–72 hours were not associated with 30-day heart failure rehospitalization or mortality (P = .065), relative changes in NTproBNP were nominally associated (P = .046). In contrast, both absolute and relative changes in NTproBNP from baseline to 48–72 hours and to 30 days were closely associated with 180-day mortality (P < .02 for all) with increased discrimination compared to the multivariable models with baseline NTproBNP (P <.05 for models with relative and absolute change at both time points). Conclusions: Although the degree of absolute change in NTproBNP was dependent on baseline levels, both short-term absolute and relative changes in NTproBNP were independently and incrementally associated with long-term clinical outcomes. Changes in NTproBNP levels at 30-days were particularly well associated with long-term clinical outcomes.

Item Type:Articles
Additional Information:Funding: The ASCEND-HF study, including the biomarker substudy, was funded by Scios Inc; Janssen Research & Development LLC retains operational responsibility for the ASCEND-HF study.
Status:Published
Refereed:Yes
Glasgow Author(s) Enlighten ID:McMurray, Professor John
Authors: Grodin, J. L., Liebo, M. J., Butler, J., Metra, M., Felker, G. M., Hernandez, A. F., Voors, A., McMurray, J. J., Armstrong, P. W., O'Connor, C., Starling, R. C., Troughton, R. C., and Tang, W.H. W.
College/School:College of Medical Veterinary and Life Sciences > Institute of Cardiovascular and Medical Sciences
Journal Name:Journal of Cardiac Failure
Publisher:Elsevier
ISSN:1071-9164
ISSN (Online):1532-8414
Published Online:04 April 2019

University Staff: Request a correction | Enlighten Editors: Update this record